|
|
 |
|
Viewing report
|
|
|
|
Partnering in the Global Generics Industry 2010 - A Guide to Companies
Espicom Business Intelligence Ltd, Oct 2010, Pages: 472
'Facts, statistics and insights on 168 medium-sized generic manufacturers from 40 countries
The operating environment for generics companies is changing rapidly as the industry matures and growth focuses on new market opportunities.
The current economic downturn has impacted the sector in terms of the number and types of deal but consolidation continues to affect the market, with a smaller number of big players dominating.
Acquisition is still a favoured route to fast market access but strategic partnering is on the rise. In such a market you need to know:
- Who are the medium-sized companies of note?
- How well do they perform?
- What drugs do they produce?
- Where are they located?
This report will tell you!
Identify merger, acquisition and partner candidates in the rapidly changing global generics market.
Consolidation and collaboration runs throughout the generic industry. Here's just a taste of the acquisitions, controlling investments and deals reported recently:
- URL Pharma acquire manufacturing assets of PharmPro
- Luitpold Pharma acquires Pharmaforce
- Hi-Tech Pharmacal acquires product line from Blaine Company
- Aspen Pharmacare acquires Sigma's pharmaceutical division
- Sun Pharmaceuticals' long expected acquisition of Taro Pharmaceuticals
- Sandoz acquires Ebewe Pharmaceuticals
- GSK acquires Stiefel
- Strides Arcolab acquires Ascent Pharmahealth
- sanofi-aventis form Japanese joint venture with Nichi-Iko
- Adcock-Ingram acquires Ghanaian manufacturer Ayrton
- Cephalon acquires Mepha
- Strategic partnering
In addition to outright purchase, strategic partnering or the acquisition of specific drug assets is on the rise as companies seek to bring lower costs and focus to their portfolios. With business cycles growing shorter and shorter, market entry is quicker, more reliable and less risky through acquisition and partnering.
The fundamental market drivers are sound
In addition to ongoing expansion, there are other drivers which are causing the generic companies to consider the future:
Over the next 5 years a number of blockbuster pharmaceutical products such as Lipitor, Cozaar, Lovenox, Plavix, Cymbalta and Seroquel will be losing patent protection.
The number of biologics coming into the remit of generic companies is increasing, raising interest in companies with biosimilars production capability.
The branded industry's response
The branded industry continues to vigorously protect its IP and maximise the lifetime value of its products. While legal initiatives will remain a key weapon there will also be commercial responses such as issuing early branded generics, collaborative working with a limited number of generic producers, new formulations or combination products.
Identify new business opportunities and assess risk
For everyone needing to evaluate the generic industry's competitive landscape, this thoroughly-researched and expanded 3rd Edition of Partnering in the Global Generics Industry 2010: A guide to companies (published October 2010) is essential reading. In 450 information-packed pages this completely revised edition references 168 generics companies operating in 40 markets around the world.
More Information:
Unbeatable coverage
For each company, where available or appropriate, the report provides:
BACKGROUND
A summary of the company's foundation and main business interests
PRODUCT RANGE
Details of ANDAs approved or products represented
FINANCIAL
Financial performance or funding data
STRATEGIC ALLIANCES
Details of significant marketing and supply agreements
CONTACT INFORMATION
Use this report to:
- Identify commercial partners
- Understand the developing generic industry in key markets worldwide
- Profile the competitive environment in the increasingly important medium-sized company sector
- Seek out companies manufacturing/marketing similar product lines
- Assess the investment potential of these developing companies
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Partnering in the Global Generics Industry 2009: A guide to companies
Partnering in the Global Generics Industry 2008: A Guide to Companies
Emerging Generic Drug Companies Worldwide 2007
GenericHandbook - A Guide to the Generic Drug Industry in the US - 3rd Edition
Specialty Generics: Climbing the value chain
Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues
Indian Pharmaceutical Industry, Q4 2011
The Future of the Generics Industry: Opportunities, Threats and Key Trends
Patent Expiry Strategies of Big Pharma
Emerging Opportunities in Controlled-Release Generic Drugs
|
|
|
|
